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THE aim of this study was to determine the role of CC
chemokine CCL6/C10 in acute inflammation. Intra-
peritoneal injection of thioglycollate increased
peritoneal CCL6, which peaked at 4 h and remained
elevated at 48 h. Neutralization of CCL6 significantly
inhibited the macrophage infiltration (34 
/48%
reduction), but not other cell types, without decreas-
ing the other CC chemokines known to attract
monocytes/macrophages. CCL6 was expressed in
peripheral eosinophils and elicited macrophages,
but not in elicited neutrophils. Peritoneal CCL6 level
was not decreased in granulocyte-depleted mice
where eosinophil influx was significantly impaired.
Thus, CCL6 appears to contribute to the macrophage
infiltration that is independent of other CC chemo-
kines. Eosinophils pre-store CCL6, but do not release
CCL6 in the peritoneum in this model of inflamma-
tion.
Key words: Acute inﬂammation, CC chemokines, Eosino-
phils, Monocytes/macrophages, Neutrophils
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Introduction
The inflammatory response is characterized by leu-
kocyte infiltration into inflammatory foci, which is
initiated and orchestrated by a variety of inflamma-
tory mediators. Of these, chemokines are a group of
cytokines that are chemotactic for specific types of
leukocyte populations.
1,2 Chemokines have been
divided mainly into two subfamilies, CXC and CC
chemokines, based on their sequence homology and
the position of cysteine residues.
3,4 CXC chemokines
are typically chemotactic for neutrophils, whereas CC
chemokines attract and activate monocytes and
lymphocytes. The role of CXC chemokine such as
CXC8/IL-8 in a variety of inflammatory diseases has
been extensively investigated.
5 CC chemokines that
include CCL2/MCP-1, CCL3/MIP-1a and CCL22/MDC
are detected in an early phase of acute inflammation,
playing an essential role in the recruitment and
activation of monocytes/macrophages.
6 10
Murine CCL6/C10, a prototype CC chemokine,
was initially identified as a transcript induced in
bone marrow cells upon stimulation with gran-
ulocyte /macrophage colony-stimulating factor.
11 It
has shown that CCL6 is present in a variety of chronic
inflammatory disorders including experimental de-
myelinating diseases, allergic airway inflammation,
bleomycin-induced lung fibrosis and chronic peri-
tonitis.
12 15 These findings demonstrate an important
role of CCL6 in chronic inflammation associated with
macrophage infiltration. However, the precise role of
CCL6 in acute inflammation remains to be elucidated.
The aim of the present study was to characterize
the role of CCL6 in acute inflammation. For this
purpose, we first examined the production kinetics of
CCL6 in a murine model of acute peritonitis induced
by thioglycollate injection. We then investigated
whether CCL6 could contribute to the leukocyte
infiltration in this model by neutralizing the endo-
genous CCL6 with antibodies against CCL6. Finally,
we attempted to determine the major cellular sources
of CCL6 using reverse transcription-polymerase chain
reaction (RT-PCR), enzyme-linked immunosorbent
assay (ELISA) and immunohistochemistry. The pre-
sent data suggest that CCL6 is an important CC
chemokine attracting monocytes/macrophages.
Although CCL6 is pre-stored in circulating eosino-
phils, the CCL6 does not appear to be released in this
particular model.
Materials and methods
Mice
Female CD-1 mice (6 /8 weeks of age) were purch-
ased from Jackson Laboratory (Bar Harbor, ME, USA)
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349and housed in the animal care facility unit (University
Laboratory of Animal Medicine). The animal use
committee at the University of Michigan approved
all studies.
Peritonitis model
The mice received intraperitoneal (i.p.) injection of 1
ml of a 2% thioglycollate broth (Difco Laboratories,
Detroit, MI, USA). To neutralize CCL6, 0.5 ml of anti-
murine CCL6 antiserum was i.p. injected 2 h prior to
thioglycollate injection. Polyclonal anti-murine CCL6
antiserum was raised by immunizing rabbits with
recombinant murine CCL6 (R&D systems Inc., Min-
neapolis, MN, USA), as previously described.
13,16 The
antibodies had a neutralizing activity against murine
recombinant CCL6 in vitro chemotaxis assay, and did
not cross-react with a number of other murine
cytokines and chemokines available (data not
shown). As a control, pre-immune rabbit serum (0.5
ml) was used. At appropriate time points following
thioglycollate injection, mice were euthanized by
cervical dislocation. Peritoneal lavages were collected
by washing the peritoneum with 2 ml of sterile saline,
were centrifuged, and cell-free peritoneal fluids were
stored at   /208C for measurements of chemokines.
Cell pellets were resuspended in saline, and the cell
numbers were counted in a hemocytometer. Differ-
ential cell analysis was made after Diff-Quik staining
of cytospin preparations.
Granulocyte depletion
Granulocytes were depleted using RB6-8C5 mono-
clonal antibody directed against Ly-6G, previously
known as Gr-1, an antigen on the surface of murine
granulocytes that includes neutrophils and eosino-
phils.
17,18 A total of 100 mg of RB6-8C5 was i.p.
administered 1 day prior to thioglycollate injection.
This resulted in peripheral blood granulopenia (B /50
cells/ml) by days 1 and 3 after the administration, with
a return of peripheral counts to pretreatment levels
by day 5.
19 Due to the granulopenia, the treatment
effectively inhibited neutrophil and eosinophil infil-
tration in animal models of inflammation.
19,20 Iso-
type-matched mouse IgG was used as a control.
Isolation of granulocytes and macrophages
Elicited granulocytes and macrophages were isolated
from the peritoneal exudates after thioglycollate
injection by Percoll gradient centrifugation. For this,
exudates from five mice or two mice were combined
in each experiment for granulocyte or macrophage
isolation, respectively. Six independent experiments
were performed. Peripheral granulocytes were iso-
lated from heparinized untreated mice blood (10
mice each, three independent experiments) by dex-
tran sedimentation, followed by Percoll gradient
centrifugation and hypotonic lysis of erythrocytes.
Diff-Quik staining of cytospin preparations showed
that the purity of granulocytes and macrophages in
each experiment was  /92% and  /94%, respectively.
Resident peritoneal macrophages were harvested
from untreated mice, and the adherent cells were
used. Isolated cells were used for RT-PCR and ELISA.
For ELISA assay, cells were extracted with phosphate-
buffered saline containing 1% Triton X-100 and
protease inhibitors (Roche Applied Science, Basel,
Switzerland).
RT-PCR
Total RNA was isolated from cells using Trizol
reagent (Life Technologines, Grand Island, NY,
USA) according to the manufacturer’s instructions.
First-strand cDNA was synthesized from 1 mgo f
total RNA with oligo (dT)12 18 as primers, and the
first-strand cDNAs were then amplified by each PCR
in the presence of Taq polymerase (Life Technolo-
gies) and specific primers. The primers were de-
signed to amplify murine CCL6 referred to the cDNA
sequence from the National Center for Biotechnology
Information database. The primers were as follows:
CCL6 sense, 5?-GACGTCATATGGGCCTCATACAAGA-
AATG-3? and antisense, 5?-TCGTGGATCCTGCCTGC-
CCTCCTTCTC-3?;GAPDHsense,5?-GGTGAAGGTCG-
GT-GTCAACGGATTT-3? and antisense, 5?-GATGC-
CAAAGTTGTCATGGATGACC-3?. The PCR reaction
was conducted at 35 cycles of 948C for 1 min, 558C for
1 min, and 728C for 1 min. Ten microlitres of each PCR
product was subjected to electrophoresis on a 2%
agarose gelin the presenceof ethidium bromide.
ELISA
Murine chemokines were quantitated using a stan-
dard method of sandwich ELISA as previously
described.
13,16,21 The captured antibodies, detection
antibodies and the recombinant cytokines were
purchased from R&D Systems. The ELISAs employed
in this study did not cross-react with other murine
cytokines, and constantly detected murine cytokines/
chemokines above 10 pg/ml.
Immunohistochemistry
Cytospin preparations were fixed in 100% ethanol for
10 min, and the endogenous neutrophil peroxidase
was blocked with 0.3% H2O2 in methanol. The slides
were rehydrated in Tris-buffered saline (TBS) and
blocked with 5% normal goat serum for 20 min at
room temperature. Staining for CCL6 was carried out
with anti-CCL6 IgG or control rabbit IgG at 5 mg/ml in
TBS /1% bovine serum albumin for 30 min at room
temperature. After washing with TBS /Tween 20
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goat anti-rabbit IgG antibodies and rinsed. The slides
were then incubated for 30 min with Vectastain Elite
ABC Reagent (Vector Laboratories, Burlingame, CA,
USA). After washing, the reaction was developed
with DAB Substrate Kit (Zymed Laboratories, San
Francisco, CA, USA). Counter-staining was done with
hematoxylin.
Statistics
Statistical significance was evaluated by an unpaired
Student’s t-test. pB /0.05 was regarded as statistically
significant. All results are expressed as mean
9 /standard error.
Results
Production of CCL6 during thioglycollate-
induced peritonitis
To determine the production kinetics of CCL6 in this
model of acute inflammation, cell-free peritoneal
fluids were collected at appropriate time points after
thioglycollate injection and CCL6 level in the fluids
were measured by ELISA. As shown in Fig. 1, levels of
CCL6 reached their peak at 4 h and the levels were
sustained for 48 h after the injection. Thus, CCL6
increased rapidly in the peritoneum and the level
remained elevated even after 48 h post-injection.
Neutralization of endogenous CCL6 reduces
macrophage infiltration
Experiments were next conducted to determine the
role of CCL6 in this model. To address this, endo-
genous CCL6 was neutralized by administration of
anti-CCL6 antiserum prior to thioglycollate injection.
The data in Fig. 2 demonstrate that neutralization of
CCL6 resulted in significant decreases in the number
of infiltrating macrophages at any time examined,
ranging from a 34% reduction to a 48% reduction
(43% reduction on average), as compared with the
control. The treatment did not affect the numbers of
infiltrating neutrophils, eosinophils, and lymphocytes
(Fig. 2). These results indicate that endogenous CCL6
is important in the recruitment of macrophages, but
not other cell types.
Effects of anti-CCL6 antiserum on the
production of other CC chemokines
To determine whether CCL6 could directly or indir-
ectly attract macrophages during inflammation, we
examined the peritoneal levels of CCL2, CCL3 and
CCL22 known to be involved in the recruitment of
macrophages
6 10 after the treatment with anti-CCL6
antibodies. Consequently, the treatment did not
decrease the CCL2 level, but rather augmented
CCL2 production, as compared with the control.
The CCL22 level was not altered by the treatment
(Fig. 3). No appreciable level of CCL3 was detected in
the peritoneum (data not shown). Thus, other
monocyte chemotactic CC chemokines were not
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FIG. 1. Production kinetics of CCL6 in the peritoneal ﬂuids
after thioglycollate injection. At indicated intervals after
thioglycollate injection, mice were euthanized and the
peritoneal ﬂuids were harvested (each point, 10 /14 mice).
CCL6 levels in the peritoneal ﬂuids were measured by ELISA.
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FIG. 2. Effects of neutralization of CCL6 on the leukocyte
inﬁltration induced by thioglycollate. Either 0.5 ml of anti-
CCL6 antiserum (closed columns) or control serum (open
columns) was intraperitoneally injected 2 h prior to thiogly-
collate injection. At indicated intervals after thioglycollate
injection, mice were euthanized and the inﬁltrating leuko-
cytes in the peritoneal cavity were harvested (each group,
10 mice). The numbers of neutrophils, eosinophils, lympho-
cytes and macrophages were then counted.
% pB /0.05,
$ pB /0.001, when compared with control.
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CCL6 may attract monocytes/macrophages indepen-
dently of other CC chemokines. Anti-CCL6 treatment
failed to alter the peritoneal level of CCL1/TCA3,
CCL5/RANTES and CCL11/Eotaxin (data not shown).
Cellular source of CCL6
We next attempted to determine the cellular source of
CCL6. First, we isolated peritoneal granulocytes and
macrophages following thioglycollate injection, and
mRNA expression in the cells was examined by RT-
PCR. Non-stimulated granulocytes and macrophages
were isolated from peripheral blood and the perito-
neum from untreated mice, respectively. As shown in
Fig. 4, CCL6 mRNA expression was not detected in
elicited granulocytes at 4 h (mean% eosinophils
  /4.4%) and 8 h (mean% eosinophils  /13.7%) after
the injection. No expression was found at 24 h
(mean% eosinophils  /13.7%; data not shown). In
contrast, not only CCL6 mRNA (Fig. 4), but also its
protein (Fig. 5) were detected in peripheral granulo-
cytes (mean% eosinophils  /23%), and the protein
level in the elicited granulocytes were gradually
decreased as compared with peripheral granulocytes
(Fig. 5). On the other hand, both CCL6 mRNA and
protein were detected in resident macrophages, and
the levels in the elicited macrophages were increased
with time during inflammation (Figs 4 and 5).
Immunohistochemically, the cells stained with anti-
CCL6 IgG were eosinophils and macrophages. Neu-
trophils were not stained with the anti-CCL6 IgG
(Fig. 6).
The aforementioned findings suggest a possibility
that eosinophils may contribute to the early phase of
macrophage influx via releasing the pre-stored CCL6
inside the cells. To address this hypothesis, granulo-
cytes were depleted from mice and peritoneal levels
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FIG. 3. Effects of anti-CCL6 treatment on CC chemokine
production. Either 0.5 ml of anti-CCL6 antiserum (closed
columns) or control serum (open columns) was intraperito-
neally injected 2 h prior to thioglycollate injection. At
indicated intervals after thioglycollate injection, mice were
euthanized and the peritoneal ﬂuids were harvested (each
group, 10 mice), and levels of CCL2 and CCL22 were
measured by ELISAs.
% pB /0.05,
’ pB /0.0001, when compared
with control.
FIG. 4. Expression of CCL6 mRNA in granulocytes and
macrophages. Inﬁltrated granulocytes and macrophages
were puriﬁed from the elicited leukocytes after thioglycollate
injection. Unstimulated granulocytes and macrophages
were puriﬁed from non-treated peripheral blood and perito-
neal cavity, respectively. Total RNA was isolated from the
cells and reverse transcribed to cDNA, and the cDNA was
ampliﬁed by speciﬁc primers for murine CCL6 and GAPDH.
Shown are representative data from three independent
experiments.
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FIG. 5. Intracellular level of CCL6. Granulocytes and macro-
phages were isolated from peripheral blood or from the
peritoneum after thioglycollate injection as indicated. CCL6
levels in cell extracts were measured with ELISA (three to
ﬁve groups at each time-point).
% pB /0.05,
$ pB /0.001, when
compared with peripheral granulocytes or resident macro-
phages.
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measured. Depletion of granulocytes resulted in
significant decreases in the number of infiltrating
neutrophils and eosinophils at 4 h and 8 h after
thioglycollate injection (Table 1). Under these condi-
tions, the peritoneal CCL6 levels were measured,
which demonstrated that levels of CCL6 were com-
parable with those in the control (Fig. 7). These
findings suggest that CCL6 in eosinophils is not
released in the peritoneum in this model.
Discussion
Inflammation is a series of well-coordinated events
that depend on sequential arrival of inflammatory
leukocytes to the site of inflammation, in which
chemokines play a central role. Our present data
suggest that CCL6 is unique in its commitment to the
development of inflammation. Production of CCL6
peaked at 4 h and the level remained elevated even at
48 h after the injection. Wu et al. demonstrated that
high level of CCL6 was detected for up to 10 days in
this model.
15 In contrast, CCL2 and CCL22, known to
attract monocytes/macrophages, peaked at 4 h after
the injection and returned to the basal level by 24 h
(own unpublished data). Neutralization of CCL6
resulted in decreases in the number of infiltrating
macrophages during the observation periods, but not
other cell types, suggesting that CCL6 governs
macrophage infiltration from the very beginning to
a late period of time, playing a role in the initiation
and maintenance of macrophage infiltration.
Macrophage infiltration is induced by multiple CC
chemokines, leading to a possibility that CCL6 might
induce macrophage infiltration indirectly via the
production of other CC chemokines known to be
involved in the recruitment of macrophages. A recent
investigation has demonstrated that CCL6 neutraliza-
tion decreased IL-13-induced CCL2 and CCL3 pro-
duction in the lung.
22 Neutralization of CCL6
decreased CCL2 production in a murine model of
allergic bronchopulmonary aspergillosis.
13 CCL6
enhanced CCL2 production in a murine model of
septic peritonitis.
16 However, the present data de-
monstrated that neutralization of CCL6 did not
decrease CCL2 as well as CCL22 levels, indicating
that CCL6 may attract monocytes/macrophages with-
out reference to other CC chemokines in this
particular model. Thus, chemokine /chemokine in-
teraction appears to be different among the types of
inflammation.
Interestingly, the CCL2 level was rather increased
by neutralization of CCL6. The mechanism by which
neutralization of CCL6 increased CCL2 in this model
remains to be elucidated. CCL6 is induced by anti-
inflammatory cytokines interleukin (IL)-4, IL-10 and
IL-13,
23 raising a possibility that CCL6 may down-
regulate the production of CCL2. However, CCL6 (1 /
100 ng/ml) failed to decrease the production of CCL2
FIG. 6. Cellular source of CCL6. Cytospin preparations of peripheral leukocytes and thioglycollate-elicited leukocytes at 8 h
were stained with anti-CCL6 IgG. E, eosinophils; M, macrophages; N, neutrophils. Shown are representative data from three
independent preparations.
Table 1. Thioglycollate-induced leukocyte inﬁltration in granulocyte-depleted mice
Neutrophils Eosinophils Lymphocytes Macrophages
4h
RB6-8C5 mAb 259 /0.15
$ 0.039 /0.01* 0.729 /0.17 3.679 /0.68
Control IgG 4.579 /0.98 0.179 /0.06 0.659 /0.12 3.689 /0.60
8h
RB6-8C5 mAb 0.829 /0.26
$ 0.149 /0.08* 0.719 /0.16 6.039 /0.87*
Control IgG 5.029 /0.96 0.429 /0.10 0.839 /0.14 9.039 /0.95
Mice were treated with RB6-8C5 monoclonal antibody (mAb) or control IgG, 1 day prior to thioglycollate injection. At 4 h and 8 h after
thioglycollate injection, mice were euthanized and the infiltrating leukocytes in the peritoneum were counted (10 mice for each time-point).
* pB /0.05,
$ pB /0.001 versus control.
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lipopolysaccharide (1 mg/ml) or thioglycollate (0.4%
v/v) in vitro (data not shown). Thus, a hypothesized
immunomodulatory activity of CCL6 is not probable.
The reason why the increased level of CCL2 itself did
not support the monocyte influx also needs to be
determined. Further studies are necessary to clarify
these points.
Consistent with a previous report,
15 cells produ-
cing CCL6 were eosinophils and macrophages, as
determined by immunohistochemistry. It is known
that eosinophils are capable of producing and
secreting a number of cytokines and chemokines.
24,25
In addition to neutrophils, eosinophils begin accu-
mulating in significant numbers in inflammation as
shown in the present study and elsewhere.
26 The
present data showed that eosinophils pre-stored
CCL6 and the level in granulocytes decreased gradu-
ally during inflammation due to the lack of its
de novo synthesis. These findings suggest that
eosinophils may release CCL6, contributing to the
subsequent macrophage infiltration. However, the
CCL6 level was not decreased in granulocyte-de-
pleted mice in which the eosinophil influx was
significantly decreased, indicating that eosinophils
did not release CCL6 in the peritoneum. Therefore,
cells other than eosinophils that may include macro-
phages appear to be the cells responsible for the
peritoneal CCL6. It should be noted that granulocyte
depletion inhibited the recruitment of macrophages
by 33% at 8 h despite the number of circulating
monocytes being unchanged. This suggests that
granulocytes that include neutrophils and eosinophils
play a role in macrophage infiltration that is inde-
pendent of CCL6 production. Neither CCL2 nor CCL3
was the factor, as these chemokine levels were not
decreased by granulocyte depletion (data not
shown).
In summary, we have demonstrated that CCL6 is an
important mediator in the recruitment of macro-
phages in acute inflammation. Thus, the present
data together with those in chronic inflammation
models suggest that CCL6 may have function in both
acute and chronic inflammatory responses. Acute
inflammation is tightly linked to T-cell-mediated
chronic inflammation, suggesting a broad activity of
CCL6 in the development and maintenance of
inflammatory disorders.
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